- Report
- October 2024
- 184 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- August 2024
- 149 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- June 2024
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- April 2025
- 200 Pages
Global
From €2266EUR$2,490USD£1,943GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- September 2023
- 180 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- January 2024
- 206 Pages
Global
From €4050EUR$4,450USD£3,472GBP
- Report
- June 2022
- 320 Pages
Global
From €12650EUR$13,900USD£10,845GBP
- Report
- June 2023
- 280 Pages
Global
From €2275EUR$2,500USD£1,951GBP

Choroidal Neovascularization (CNV) is a condition in which abnormal blood vessels grow beneath the retina in the eye. It is a major cause of vision loss in age-related macular degeneration (AMD). Optical treatments for CNV include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to destroy the abnormal blood vessels and prevent further vision loss. Photodynamic therapy uses a light-activated drug to destroy the abnormal vessels. Anti-VEGF injections are used to block the growth of new vessels and reduce fluid leakage.
The CNV market is highly competitive, with a number of companies offering treatments and products. These include Novartis, Regeneron, Allergan, Roche, Bayer, and Santen Pharmaceuticals. Show Less Read more